{
    "root": "316d17d0-4fb7-a200-e063-6394a90aa5e2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sulfamethoxazole and Trimethoprim",
    "value": "20250328",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32112"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED",
            "code": "K679OBS311",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SORBITOL SOLUTION",
            "code": "8KW3E207O2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_75958"
        },
        {
            "name": "SULFAMETHOXAZOLE",
            "code": "JE42381TNV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9332"
        },
        {
            "name": "TRIMETHOPRIM",
            "code": "AN164J8Y0X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_45924"
        }
    ],
    "indications": {
        "text": "reduce development drug-resistant bacteria maintain effectiveness sulfamethoxazole trimethoprim oral suspension antibacterial drugs , sulfamethoxazole trimethoprim oral suspension used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy . urinary tract infections treatment urinary tract infections due susceptible strains following organisms : escherichia coli , klebsiella species , enterobacter species , morganella morganii , proteus mirabilisand proteus vulgaris . recommended initial episodes uncomplicated urinary tract infections treated single effective antibacterial agent rather combination . acute otitis media treatment acute otitis media pediatric patients due susceptible strains streptococcus pneumoniaeor haemophilus influenzaewhen judgment physician sulfamethoxazole trimethoprim offers advantage antimicrobial agents . date , limited data safety repeated sulfamethoxazole trimethoprim pediatric patients two years age . sulfamethoxazole trimethoprim indicated prophylactic prolonged otitis media age . acute exacerbations chronic bronchitis adults treatment acute exacerbations chronic bronchitis due susceptible strains streptococcus pneumoniaeor haemophilus influenzaewhen physician deems sulfamethoxazole trimethoprim could offer advantage single antimicrobial agent . shigellosis treatment enteritis caused susceptible strains shigella flexneriand shigella sonnei antibacterial therapy indicated . pneumocystis jirovecii pneumonia treatment documented pneumocystis jiroveciipneumonia prophylaxis p. jiroveciipneumonia individuals immunosuppressed considered increased risk developing p. jirovecii pneumonia . traveler \u2019 diarrhea adults treatment traveler \u2019 diarrhea due susceptible strains enterotoxigenic e. coli .",
        "doid_entities": [
            {
                "text": "otitis media (DOID:10754)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10754"
            },
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "shigellosis (DOID:12385)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12385"
            },
            {
                "text": "pneumocystis jirovecii pneumonia (DOID:11339)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11339"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "diarrhea (DOID:13250)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13250"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute otitis media",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "contraindications": {
        "text": "sulfamethoxazole trimethoprim oral suspension contraindicated pediatric patients less 2 months age . urinary tract infections shigellosis adults pediatric patients , acute otitis media children adults : usual adult treatment urinary tract infections 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim oral suspension every 12 hours 10 14 days . identical daily used 5 days treatment shigellosis . children : recommended dose children urinary tract infections acute otitis media 40 mg/kg sulfamethoxazole 8 mg/kg trimethoprim per 24 hours , given two divided doses every 12 hours 10 days . identical daily used 5 days treatment shigellosis . following table guideline attainment : children 2 months age older : weight dose - every 12 hours lb kg teaspoonfuls 22 10 1 ( 5 ml ) 44 20 2 ( 10 ml ) 66 30 3 ( 15 ml ) 88 40 4 ( 20 ml ) patients impaired renal function renal function impaired , reduced employed using following table : creatinine clearance ( ml/min ) recommended regimen 30 usual standard regimen 15-30 1\u20442 usual regimen 15 recommended acute exacerbations chronic bronchitis adults usual adult treatment acute exacerbations chronic bronchitis 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim oral suspension every 12 hours 14 days . pneumocystis jirovecii pneumonia treatment adults children : recommended treatment patients documented pneumocystis jiroveciipneumonia 75 100 mg/kg sulfamethoxazole 15 20 mg/kg trimethoprim per 24 hours given equally divided doses every 6 hours 14 21 days . 12the following table guideline upper limit : weight dose - every 6 hours lb kg teaspoonfuls 18 8 1 ( 5 ml ) 35 16 2 ( 10 ml ) 53 24 3 ( 15 ml ) 70 32 4 ( 20 ml ) 88 40 5 ( 25 ml ) 108 48 6 ( 30 ml ) 141 64 8 ( 40 ml ) 176 80 10 ( 50 ml ) lower limit dose ( 75 mg/kg sulfamethoxazole 15 mg/kg trimethoprim per 24 hours ) administer 75 % dose table . prophylaxis adults : recommended prophylaxis adults 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim oral suspension daily . 13 children : children , recommended dose 750 mg/m 2/day sulfamethoxazole 150 mg/m 2/day trimethoprim given orally equally divided doses twice day , 3 consecutive days per week . total daily dose exceed 1,600 mg sulfamethoxazole 320 mg trimethoprim . 14the following table guideline attainment children : body surface area dose - every 12 hours ( 2 ) teaspoonfuls 0.26 1/2 ( 2.5 ml ) 0.53 1 ( 5 ml ) 1.06 2 ( 10 ml ) traveler \u2019 diarrhea adults treatment traveler \u2019 diarrhea , usual adult 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim oral suspension every 12 hours 5 days .",
        "doid_entities": [
            {
                "text": "shigellosis (DOID:12385)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12385"
            },
            {
                "text": "otitis media (DOID:10754)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10754"
            },
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "pneumocystis jirovecii pneumonia (DOID:11339)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11339"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "diarrhea (DOID:13250)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13250"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute otitis media",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "warningsAndPrecautions": "sulfamethoxazole trimethoprim oral suspension , usp ( cherry flavor ) , opaque , pinkish orange suspension cherry aroma , containing 40 mg trimethoprim 200 mg sulfamethoxazole teaspoonful ( 5 ml ) , available one pint ( 473 ml ) bottle ndc 62135-749-47 , 20 ml unit-dose cup ndc 62135-873-52 20 unit-dose cups 20 ml ndc 62135-873-24. store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] protect light . dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . report suspected , contact chartwell rx , llc . 1-845-232-1683 fda 1-800-fda-1088 www.fda.gov/medwatch . references 1. kremers p , duvivier j , heusghem c. pharmacokinetic co-trimoxazole man single repeated doses . j clin pharmacol . feb-mar 1974 ; 14:112\u2013117 . 2. kaplan sa , et al . pharmacokinetic profile trimethoprim-sulfamethoxazole man . j infect dis . nov 1973 ; 128 ( suppl ) : s547\u2013s555 . 3. varoquaux , et al . pharmacokinetics trimethoprim-sulfamethoxazole combination elderly . br j clin pharmacol . 1985 ; 20:575\u2013581 . 4. safrin , lee bl , sande . adjunctive folinic acid trimethoprim-sulfamethoxazole pneumocystis carinii pneumonia aids patients associated increased risk therapeutic failure death . j infect dis . 1994 oct ; 170 ( 4 ) : 912\u20137 . 5. marinella mark . 1999. trimethoprim-induced hyperkalemia : analysis reported cases . gerontol.45:209\u2013212 . 6. margassery , s. b. bastani . 2002. life threatening hyperkalemia acidosis secondary trimethoprim-sulfamethoxazole treatment . j. nephrol.14:410\u2013414 . 7. moh r , et al . haematological changes adults receiving zidovudine-containing haart regimen combination cotrimoxazole c\u00f4te d'ivoire . antivir ther . 2005 ; 10 ( 5 ) : 615-24 . 8. al-khatib sm , lapointe n , kramer jm , califf rm . clinicians know qt interval . jama . 2003 ; 289 ( 16 ) : 2120-2127 . 9. boyer ew , stork c , wang ry . review : pharmacology toxicology dofetilide . int j med toxicol . 2001 ; 4 ( 2 ) : 16 . 10. kosoglou , rocci ml jr , vlasses ph . trimethoprim alters disposition procainamide n-acetylprocainamide . clin pharmacol ther . oct 1988 ; 44 ( 4 ) : 467-77 . 11. brumfitt w , pursell r. trimethoprim/sulfamethoxazole treatment bacteriuria women . j infect dis . nov 1973 ; 128 ( suppl ) : s657\u2013s663 . 12. masur h. prevention treatment pneumocystis pneumonia . n engl j med.1992 ; 327 : 1853\u20131880 . 13. recommendations prophylaxis pneumocystis carinii pneumonia adults adolescents infected human immunodeficiency virus . mmwr . 1992 ; 41 ( rr-4 ) : 1\u201311 . 14. cdc guidelines prophylaxis pneumocystis carinii pneumonia children infected human immunodeficiency virus . mmwr . 1991 ; 40 ( rr-2 ) : 1\u201313 . trademarks property respective owners . manufactured : chartwell rx , llc . congers , ny 10920 l71664 rev . 03/2025",
    "adverseReactions": "sulfamethoxazole trimethoprim contraindicated following situations : known hypersensitivity trimethoprim sulfonamides history drug-induced immune thrombocytopenia trimethoprim and/or sulfonamides documented megaloblastic anemia due folate deficiency pediatric patients less 2 months age marked hepatic damage severe renal insufficiency renal function status monitored concomitant dofetilide ( ) .",
    "indications_original": "To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim oral suspension and other antibacterial drugs, sulfamethoxazole and trimethoprim oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.\n                  \n                     \n                        Urinary Tract Infections\n                     \n                  \n                  For the treatment of urinary tract infections due to susceptible strains of the following organisms:\u00a0\n \n  Escherichia coli,\u00a0Klebsiella species,\u00a0Enterobacter species, Morganella morganii,\u00a0Proteus mirabilisand\n \n  Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.\n\n \n                  \n                     \n                        Acute Otitis Media\n                     \n                  \n                  For the treatment of acute otitis media in pediatric patients due to susceptible strains of\n \n  Streptococcus pneumoniaeor\n \n  Haemophilus influenzaewhen in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim is not indicated for prophylactic or prolonged administration in otitis media at any age.\n\n \n                  \n                     \n                        Acute Exacerbations of Chronic Bronchitis in Adults\n                     \n                  \n                  For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of\n \n  Streptococcus pneumoniaeor\n \n  Haemophilus influenzaewhen a physician deems that sulfamethoxazole and trimethoprim could offer some advantage over the use of a single antimicrobial agent.\n\n \n                  \n                     \n                        Shigellosis\n                     \n                  \n                  For the treatment of enteritis caused by susceptible strains of\n \n  Shigella flexneriand\n \n  Shigella sonnei\u00a0when antibacterial therapy is indicated.\n\n \n                  \n                     \n                        \n                           Pneumocystis jirovecii\u00a0\n                        \n                     \n                     \n                        Pneumonia\n                     \n                  \n                  For the treatment of documented\n \n  Pneumocystis jiroveciipneumonia and for prophylaxis against\n \n  P. jiroveciipneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing\n \n  P. jirovecii\u00a0pneumonia.\n\n \n                  \n                     \n                        Traveler\u2019s Diarrhea in Adults\n                     \n                  \n                  For the treatment of traveler\u2019s diarrhea due to susceptible strains of enterotoxigenic\n \n  E. coli.",
    "contraindications_original": "Sulfamethoxazole and trimethoprim oral suspension is contraindicated in pediatric patients less than 2 months of age.\n                  \n                     \n                        Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children\n                     \n                  \n                  \n                     Adults:\u00a0The usual adult dosage in the treatment of urinary tract infections is 4 teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim oral suspension every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.\n\n \n                  \n                     Children:\u00a0The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage:\n\n \n                  \n                     Children 2 months of age or older:\n                  \n                  \n                     \n                        \n                           \n                              Weight\n                           \n                           \n                              Dose - every 12 hours\n                           \n                        \n                        \n                           \n                              lb\n                           \n                           \n                              kg\n                           \n                           \n                              Teaspoonfuls\n                           \n                        \n                        \n                           \n                              22\n                           \n                           \n                              10\n                           \n                           \n                              1 (5 mL)\n                           \n                        \n                        \n                           \n                              44\n                           \n                           \n                              20\n                           \n                           \n                              2 (10 mL)\n                           \n                        \n                        \n                           \n                              66\n                           \n                           \n                              30\n                           \n                           \n                              3 (15 mL)\n                           \n                        \n                        \n                           \n                              88\n                           \n                           \n                              40\n                           \n                           \n                              4 (20 mL)\n                           \n                        \n                     \n                  \n                  \n                     \n                        For Patients with Impaired Renal Function\n                     \n                  \n                  When renal function is impaired, a\u00a0reduced dosage should be employed using the following table:\n                  \n                     \n                        \n                           \n                              Creatinine Clearance (mL/min)\n                           \n                           \n                              Recommended Dosage Regimen\n                           \n                        \n                        \n                           \n                              Above 30\n                           \n                           \n                              Usual standard regimen\n                           \n                        \n                        \n                           \n                              15-30\n                           \n                           \n                              1\u20442 the usual regimen\n                           \n                        \n                        \n                           \n                              Below 15\n                           \n                           \n                              Use not recommended\n                           \n                        \n                     \n                  \n                  \n                     \n                        Acute Exacerbations of Chronic Bronchitis in Adults\n                     \n                  \n                  The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 4 teaspoonfuls (20 mL) sulfamethoxazole and trimethoprim oral suspension every 12 hours for 14 days.\n                  \n                     \n                        \n                           Pneumocystis jirovecii\n                        \n                     \n                     \n                        Pneumonia\n                     \n                  \n                  \n                     \n                        Treatment\n                     \n                  \n                  \n                     Adults and Children:\n                  \n                  The recommended dosage for treatment of patients with documented\n \n  Pneumocystis jiroveciipneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days.\n \n  12The following table is a guideline for the upper limit of this dosage:\n\n \n                  \n                     \n                        \n                           \n                              Weight\n                           \n                           \n                              Dose - every 6 hours\n                           \n                        \n                        \n                           \n                              lb\n                           \n                           \n                              kg\n                           \n                           \n                              Teaspoonfuls\n                           \n                        \n                        \n                           \n                              18\n                           \n                           \n                              8\n                           \n                           \n                              1 (5 mL)\n                           \n                        \n                        \n                           \n                              35\n                           \n                           \n                              16\n                           \n                           \n                              2 (10 mL)\n                           \n                        \n                        \n                           \n                              53\n                           \n                           \n                              24\n                           \n                           \n                              3 (15 mL)\n                           \n                        \n                        \n                           \n                              70\n                           \n                           \n                              32\n                           \n                           \n                              4 (20 mL)\n                           \n                        \n                        \n                           \n                              88\n                           \n                           \n                              40\n                           \n                           \n                              5 (25 mL)\n                           \n                        \n                        \n                           \n                              108\n                           \n                           \n                              48\n                           \n                           \n                              6 (30 mL)\n                           \n                        \n                        \n                           \n                              141\n                           \n                           \n                              64\n                           \n                           \n                              8 (40 mL)\n                           \n                        \n                        \n                           \n                              176\n                           \n                           \n                              80\n                           \n                           \n                              10 (50 mL)\n                           \n                        \n                     \n                  \n                  For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table.\n                  \n                     \n                        Prophylaxis\n                     \n                  \n                  \n                     Adults:\n                  \n                  The recommended dosage for prophylaxis in adults is 4 teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim oral suspension daily.\n \n  13\n                  \n                  \n                     Children:\n                  \n                  For children, the recommended dose is 750 mg/m\n \n  2/day sulfamethoxazole with 150 mg/m\n \n  2/day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1,600 mg sulfamethoxazole and 320 mg trimethoprim.\n \n  14The following table is a guideline for the attainment of this dosage in children:\n\n \n                  \n                     \n                        \n                           \n                              Body Surface Area\n                           \n                           \n                              Dose - every 12 hours\n                           \n                        \n                        \n                           \n                              (m\n     \n      2)\n    \n     \n                           \n                           \n                              Teaspoonfuls\n                           \n                        \n                        \n                           \n                              0.26\n                           \n                           \n                              1/2 (2.5 mL)\n                           \n                        \n                        \n                           \n                              0.53\n                           \n                           \n                              1 (5 mL)\n                           \n                        \n                        \n                           \n                              1.06\n                           \n                           \n                              2 (10 mL)\n                           \n                        \n                     \n                  \n                  \n                     \n                        Traveler\u2019s Diarrhea in Adults\n                     \n                  \n                  For the treatment of traveler\u2019s diarrhea, the usual adult dosage is 4 teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim oral suspension every 12 hours for 5 days.",
    "warningsAndPrecautions_original": "Sulfamethoxazole and Trimethoprim Oral Suspension, USP (Cherry Flavor), opaque, pinkish orange suspension with a cherry aroma, containing 40 mg trimethoprim and 200 mg sulfamethoxazole in each teaspoonful (5 mL), and is available in a one pint (473 mL) bottle NDC 62135-749-47, 20 mL Unit-Dose Cup NDC 62135-873-52 and 20 Unit-Dose Cups of 20 mL each NDC 62135-873-24.\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature] and protect from light.\n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  \n                     To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC. at 1-845-232-1683 or FDA at 1-800-FDA-1088 or  \n   \n                           www.fda.gov/medwatch\n                        . \n  \n                  \n                  \n                     REFERENCES\n                  \n                  1. Kremers P, Duvivier J, Heusghem C. Pharmacokinetic Studies of Co-Trimoxazole in Man after Single and Repeated Doses. \n  J Clin Pharmacol. Feb-Mar 1974;14:112\u2013117.\n \n                  2. Kaplan SA, et al. Pharmacokinetic Profile of Trimethoprim-Sulfamethoxazole in Man.  \n  J Infect Dis. Nov 1973; 128 (Suppl): S547\u2013S555.\n \n                  3. Varoquaux O, et al. Pharmacokinetics of the trimethoprim-sulfamethoxazole combination in the elderly. \n  Br J Clin Pharmacol. 1985;20:575\u2013581.\n \n                  4. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for \n  Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. \n  J Infect Dis. 1994 Oct;170(4):912\u20137.\n \n                  5. Marinella Mark A. 1999. Trimethoprim-induced hyperkalemia: An analysis of reported cases. \n  Gerontol.45:209\u2013212.\n \n                  6. Margassery, S. and B. Bastani. 2002. Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment. \n  J. Nephrol.14:410\u2013414.\n \n                  7. Moh R, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in C\u00f4te d'Ivoire.  \n  Antivir Ther. 2005;10(5):615-24.\n \n                  8. Al-Khatib SM, LaPointe N, Kramer JM, Califf RM. What Clinicians Should Know About the QT Interval. \n  JAMA. 2003;289(16):2120-2127.\n \n                  9. Boyer EW, Stork C, Wang RY. Review: The Pharmacology and Toxicology of Dofetilide. \n  Int J Med Toxicol. 2001;4(2):16.\n \n                  10. Kosoglou T, Rocci ML Jr, Vlasses PH. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. \n  Clin Pharmacol Ther. Oct 1988;44(4):467-77.\n \n                  11. Brumfitt W, Pursell R. Trimethoprim/Sulfamethoxazole in the Treatment of Bacteriuria in Women. \n  J Infect Dis. Nov 1973; 128 (Suppl): S657\u2013S663.\n \n                  12. Masur H. Prevention and treatment of \n  Pneumocystis pneumonia. \n  N Engl J Med.1992; 327: 1853\u20131880.\n \n                  13. Recommendations for prophylaxis against \n  Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. \n  MMWR. 1992; 41(RR-4):1\u201311.\n \n                  14. CDC Guidelines for prophylaxis against \n  Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. \n  MMWR. 1991; 40(RR-2):1\u201313.\n \n                  All trademarks are the property of their respective owners.\n                  \n                     Manufactured for:\n                  \n                  Chartwell RX, LLC.\n                  Congers, NY 10920\n                  L71664\n                  Rev. 03/2025",
    "adverseReactions_original": "Sulfamethoxazole and trimethoprim is contraindicated in the following situations:\n                  \n                     known hypersensitivity to trimethoprim or sulfonamides\n                     history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides\n                     documented megaloblastic anemia due to folate deficiency\n                     pediatric patients less than 2 months of age\n                     marked hepatic damage\n                     severe renal insufficiency when renal function status cannot be monitored\n                     concomitant administration with dofetilide (see\n  \n   \n                           PRECAUTIONS\n                        ).",
    "drug": [
        {
            "name": "Sulfamethoxazole and Trimethoprim",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9332"
        }
    ]
}